Cinctive Capital Management LP Neurocrine Biosciences Inc Transaction History
Cinctive Capital Management LP
- $1.78 Billion
- Q2 2025
A detailed history of Cinctive Capital Management LP transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cinctive Capital Management LP holds 4,766 shares of NBIX stock, worth $679,869. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,766Holding current value
$679,869% of portfolio
0.03%Shares
11 transactions
Others Institutions Holding NBIX
# of Institutions
662Shares Held
102MCall Options Held
290KPut Options Held
214K-
Black Rock Inc. New York, NY14.2MShares$2.02 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.81MShares$1.4 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.57MShares$794 Million0.42% of portfolio
-
State Street Corp Boston, MA4.47MShares$637 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.09MShares$440 Million0.04% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.6B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...